News from Monday, April 21, 2025
Articles
Lasmiditan Shows Promise for Menstrual Migraine, Requires Further Safety Research
(4/21, Rajan Saha, Neurology Advisor) reports “Lasmiditan is a promising treatment for menstrual migraine, offering sustained pain relief comparable to or exceeding that of triptans. However, further research is needed to fully assess its safety profile. These study results were published in Pain Therapy.” Full
NCQA’s Eric Musser on the Future of Digital Quality Measurement
(4/21, David Raths, Healthcare Innovation) reports “...[Eric Musser, vice president of federal affairs for NCQA:] There have been some efforts to date on patient-reported outcome measures. I would agree that is in the early stages of adoption in programs. NCQA has been on a decade-long journey around our person-centered outcome measures, and has tested them across provider settings. There are some that are ready to be implemented in federal and state-level programs, and we're seeing some promising results from some of those state level implementations.” Full
Industry Highlights Issues With EU HTA Regulation’s PICO Framework For Vaccines
(4/21, Eliza Slawther, Pink Sheet) reports “...EU-level joint clinical assessments (JCAs) will apply for vaccines under the HTA Regulation from 2030, but manufacturers are concerned that the framework to be used by assessors is unsuitable for vaccines.” Subscription Required
Press Releases
ISPOR Publishes Insights From Its First Global HTA Roundtable
(4/21, ISPOR Press Release) “...‘ISPOR is committed to supporting events like the Global HTA Roundtable to foster collaboration, consensus, and the evolution of HTA methodologies,’ said ISPOR CEO and Executive Director, Rob Abbott. ‘ISPOR’s Global HTA Roundtable ties directly to 2 objectives in the Society’s new Strategic Plan 2030, including proactively horizon scanning to establish high-leverage health policy opportunities that the Society can contribute toward. It also engages broadly with stakeholders to increase the visibility and influence of health economics and outcomes research, which is vital to HTA.’” Full
Journals
Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-Analysis
Zhaoming Song, et al.
February 24, 2025, Pain and Therapy
The Importance of Global Collaboration and Knowledge Exchange: A Summary Report of the Global ISPOR HTA Roundtable
March/April 2025, Value & Outcomes Spotlight
Strengthening Health Technology Assessment for Cancer Treatments in Europe by Integrating Causal Inference and Target Trial Emulation
Heiner C Bucher, Frédérique Chammartin
April 9, 2025, The Lancet Regional Health
Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study
Chun-Tse Hung, Yu-Chien Hung, Chi-Won Suk
April 16, 2025, The Journal of Allergy and Clinical Immunology
Why Isn’t Distributional Cost-Effectiveness Analysis Ready for Prime Time in HTA?
Sreeram V. Ramagopalan, PhD
April 19, 2025, Value in Health
Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial
Kara M Magane, et al.
April 21, 2025, JAMA Internal Medicine